Cyteir Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Lexington, mass.--(business wire)--cyteir therapeutics, inc. (“cyteir”) (nasdaq: cyt) today announced that it has formally notified the nasdaq stock market (“nasdaq”) of its intent to delist the company's common stock from the nasdaq global select market. cyteir expects to file a form 25 (notification of removal from listing) with the securities and exchange commission (the “sec”) relating to the voluntary delisting of its common stock on or about march 18, 2024 and has requested that the tradi.

Lexington, mass.--(business wire)--cyteir therapeutics, inc. (“cyteir”) (nasdaq: cyt) today presented ongoing results from a dose expansion cohort in its phase 1 combination study of cyt-0851 with capecitabine in patients with platinum-refractory or -resistant ovarian cancer in a late-breaker poster titled “phase 1 dose expansion results of cyt-0851, a monocarboxylate transporter (mct) inhibitor, in combination with capecitabine in platinum-resistant ovarian cancer” (poster: lb_a13) at the 2023.

Lexington, mass.--(business wire)--cyteir therapeutics, inc. (“cyteir”) (nasdaq: cyt), a clinical stage oncology company, today reported financial results for the first quarter ended march 31, 2023 and provided an update on recent operational highlights. “we have made encouraging progress enrolling patients in the cyt-0851 phase 1 combination trial with capecitabine and gemcitabine, while maintaining our strong financial discipline,” said markus renschler, md, president and chief executive officer of cyteir. “we look forward to sharing preliminary data on the phase 1 combination cohorts with cyt-0851 in mid-year.” recent updates to the cyt-0851 clinical program enrollment in the phase 1 trial with cyt-0851 in combination with capecitabine in advanced ovarian cancer continues at the 400mg dose of cyt-0851, which was determined to be the recommended phase 2 dose in the capecitabine combination...

Lexington, mass.--(business wire)--cyteir therapeutics, inc. (“cyteir”) (nasdaq: cyt), a clinical stage oncology company, today reported financial results for the fourth quarter and full year ended december 31, 2022 and provided an update on recent operational highlights. “we continue to be encouraged by the early clinical activity of cyt-0851 in ovarian cancer and are committed to bringing cyt-0851 to patients,” said markus renschler, md, president and chief executive officer of cyteir. “our significant cash runway gives us the resources to focus our development on cyt-0851 and into a potentially registrational trial as early as the second half of 2024.” recent updates to the cyt-0851 clinical program in january, cyteir reported encouraging preliminary clinical activity in the phase 1 dose escalation cohorts with cyt-0851, an investigational oral monocarboxylate transporter inhibitor, in combination with capecitabine for the treatment of advanced ovarian cancer...

Lexington, mass.--(business wire)--cyteir therapeutics, inc. (“cyteir”) (nasdaq: cyt) today announced the strategic prioritization of clinical development of cyt-0851, an investigational monocarboxylate transporter inhibitor, as a potential combination therapy for the treatment of ovarian cancer. the prioritization follows encouraging preliminary clinical activity in a small number of patients observed in the phase 1 dose escalation cohort with cyt-0851 in combination with capecitabine in advanced ovarian cancer. cyteir plans to expand its evaluation of cyt-0851 in combination with capecitabine to treat advanced ovarian cancer and enroll additional patients in the first half of 2023 to further support these early signals...

Cyteir is a developer of cancer therapeutics that has decided to suspend operations and sell all assets. Their lead candidate, CYT-0851, is an MCT1 inhibitor being investigated in combination with chemotherapy drugs. The drug has shown monotherapy activity in a phase 1 trial, but further development has been suspended.

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022. Morgan Stanley 20th Annual Global Healthcare Conference Date: Wednesday, September 14 Time:

Cyteir Therapeutics, Inc. (CYT) CEO Dr. Markus Renschler on Q4 2021 Results - Earnings Call Transcript

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a conference call and live audio webcast on Wednesday, March 16, 2022 at 4:30 p.m. ET to discuss fourth quarter and full year 2022 financial and operational results. The live audio webcast can be accessed via the Investor Relations section of the Company's website at www.cyteir.com. The a

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer was added as a member of the U.S. small-cap Russell 2000® Index, effective after the US market opens on September 20, as part of the 2021 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 300

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference, being held virtually on September 10, 2021, at 11:45am ET. A live webcast of the fireside chat will be available in the I

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in the 2021 Wedbush PacGrow Healthcare Conference, being held virtually on August 10, 2021. 12th Annual Wedbush PacGrow Healthcare Virtual Conference Date: Tuesday, August 10 Time: 11:30 AM EDT Panel: Syn

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the closing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share. All of the shares are being offered by Cyteir. In addition, Cyteir has granted the underwriters a 30-day option to purchase up to an additional